Livdelzi Hits 75.4% ALP Normalization at Week 52 in Phase 3 PBC Study
GILD sits 49% above its 52-week low of $116.88 on light trading volume (0.3× avg).
Summary
Gilead's Phase 3 IDEAL study showed 75.4% of Livdelzi (seladelpar) patients reached ALP normalization at week 52 versus 16.1% on placebo — a roughly four-and-a-half-fold gap in the second-line PBC population. Safety cut the other way too: serious adverse events were 3.1% on Livdelzi versus 12.9% on placebo, with none drug-related. The data strengthen the label story for a drug already approved, giving Gilead hard long-term normalization numbers to take to payers and prescribers rather than just biochemical response rates. It lands two weeks after the Q3 beat and raised 2026 product sales guidance of $31.0-31.3 billion, and follows the October 19 emvistegrast ulcerative colitis win — a run of clinical positives that supports the base business. Modest near-term revenue impact since Livdelzi is already on the market; the value is in share gains within PBC and payer leverage.
At the time of this announcement, GILD was trading at $174.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $216.5B. The 52-week trading range was $116.88 to $176.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.